Droplet IV Secures $2 Million for Automatic IV-Line Flushing Device

Droplet IV has successfully completed a $2 million funding round to support the launch of its automatic IV-line flushing device in the EU and US markets by 2026, announced in a press release. The device aims to address the time-consuming manual process nurses currently face when flushing IV lines to clear residual medication.

The funding marks Droplet IV's first external investment and includes contributions from healthcare investors such as a former executive of ConvaTec and members of MedTech family offices. This investment brings Droplet IV's total funding to over $5 million, which includes more than $3 million in non-dilutive grants and previous funding from the BioInnovation Institute.

The company plans to use the capital to complete final regulatory and clinical milestones necessary for the product's commercial launch. The automatic IV flushing device is expected to fill a critical gap in IV medication safety and efficiency, providing a streamlined solution for hospitals worldwide.

Droplet IV is focused on developing medical devices that improve IV medication safety and efficiency, with its new product gaining recognition in clinical settings for its potential to reduce variability and error in medication dosing.